Xenon Pharmaceuticals Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| XENE | PRAX | JAZZ | RAPP | AXSM | BHVN | |
|---|---|---|---|---|---|---|
| Market cap | 3.47B | 7.02B | 14.07B | 1.45B | 8.70B | 1.78B |
| P/E (TTM) | — | — | 14.9 | — | — | — |
| Forward P/E | -7.6 | -26.9 | 8.4 | -5.9 | 35.6 | -6.3 |
| Price/book | 2.8 | 5.2 | 2.9 | 3.4 | 104.2 | 145.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −8.88% | +396.48% | +61.62% | +17.03% | +34.39% | −21.05% |
| Today | −1.73% | −3.26% | −0.76% | −1.63% | −1.40% | −2.24% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All XENE news ›Head to Head Survey: Xenon Pharmaceuticals (NASDAQ:XENE) vs. United Therapeutics (NASDAQ:UTHR)
Posted by Kim Johansen on Oct 12th, 2026 Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) and United Therapeutics (NASDAQ:UTHR – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the…
Xenon Pharmaceuticals (NASDAQ:XENE) Sets New 1-Year Low – Here’s Why
Posted by Tristan Rich on Oct 6th, 2026 Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) shares hit a new 52-week low during mid-day trading on Tuesday. The stock traded as low as $36.02 and last traded at $35.9350, with a volume…
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
The Manila Times The share options have an exercise price of $38.93 per common share, which is equal to the closing price per share of Xenon’s common shares on the grant date of October 1, 2026. The share option grants vest over four…
Xenon rises on insider buys from CEO and CFO (XENE:NASDAQ)
Seeking Alpha - Shares of Xenon Pharmaceuticals (XENE) spiked on Thursday after the CEO and CFO of the Canadian drug developer collectively bought nearly $1.7M worth of company stock following a sharp selloff last month. - According to a…
Xenon’s Insider Buying Tops $1.6M – XENE Stock Heads For Best Day In Over Month
Xenon Pharmaceuticals (XENE) was on investors’ radar on Thursday after the biotech company’s top executives bought a combined $1.68 million in shares, as the company advances its lead epilepsy drug, Azetukalner. On Thursday, CEO Ian…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
cnbc.com2
-
themarketsdaily.com2
-
daily-tribune.com1
-
manilatimes.net1
-
seekingalpha.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 9 articles, not a forecast.